Towards tris(diimine)-ruthenium(II) and bis(quinoline)-Re(I)(CO)3 complexes as photoactivated anticancer drug candidates

Tanmaya Joshi, Gilles Albert Gasser

Research output: Contribution to journalArticleResearchpeer-review

19 Citations (Scopus)


The clinical success of cisplatin continues to inspire the development of metal-based anticancer drug candidates. This article is meant to present the current state-of-the-art and science of ruthenium(II)- and rhenium(I)-based anticancer drug candidates born out of our work in this field. Our recent efforts to elicit photoactivation of intact (organo)metallic anticancer drug candidates as a promising way for commanding their activity within cancer cells are also briefly summarized. 1 Introduction 2 Ruthenium(II) Complexes 3 Rhenium(I) Complexes 4 Concluding Remarks
Original languageEnglish
Pages (from-to)275-284
Number of pages10
Issue number3
Publication statusPublished - 2015


  • antitumor agents,
  • carbonyl complexes
  • drugs
  • medicinal chemistry
  • ruthenium
  • photochemistry

Cite this